LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.00 million for the 12-month period ending 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $1.00M, a 33.33% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $1.50M, a 36.36% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.10M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2024-05-26 | $1.00M 10-K · filed 2024-08-26 |
| 2023-05-28 | $1.50M 10-K · filed 2024-08-26 |
| 2022-05-29 | $1.10M 10-K · filed 2024-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |